Can peptides other than HGH reliably increase height?
Human studies of CJC-1295 and MK-677 cited for this topic measured hormone levels over short periods, not an increase in final height. The non-HGH medicine with a growth indication is mecasermin (recombinant IGF-1), and its U.S. label is limited to specific pediatric diagnoses. GnRH agonists address central precocious puberty, not ordinary short stature. These distinct indications and outcomes should not be combined into a general ranking of “height peptides.”
What does the mecasermin label cover?
The current U.S. INCRELEX label indicates mecasermin for growth failure in pediatric patients age 2 years and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion and neutralizing antibodies to growth hormone. The label defines severe primary IGF-1 deficiency using very low height and IGF-1 standard deviation scores with normal or elevated growth hormone. It is not a substitute for growth hormone in approved growth hormone indications and is not indicated for secondary IGF-1 deficiency such as growth hormone deficiency.
In pooled clinical studies, 71 children with severe primary IGF-1 deficiency were studied. For 61 children treated for at least one year, mean height velocity increased from 2.8 cm per year at baseline to 8.0 cm per year during year one. This is a change in growth velocity in a narrowly defined group, not a general forecast of extra adult height.
What do GnRH agonists establish about height?
GnRH agonists are used in selected children with central precocious puberty. The 2026 Endocrine Society guideline emphasizes that expected adult-height benefit varies by age, pubertal progression, and bone age; some subgroups may have little expected height benefit. This is condition-specific care for early puberty, not a height-enhancement option for otherwise healthy children or adults. The former numerical height-gain range was not tied to a defined trial population or outcome and has been removed.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What did the CJC-1295 human study measure?
Teichman and colleagues studied healthy adults ages 21 to 61 in short randomized trials. The measured outcomes were pharmacokinetics and blood growth hormone and IGF-1 levels. The study reported increases in those hormone measurements; it did not study children, growth-plate activity, height velocity, or adult height. A hormone-marker change is not a measured height result.
What did the MK-677 study in children measure?
The cited study enrolled 18 prepubertal children with idiopathic growth hormone deficiency and assigned short seven-day periods of ibutamoren or placebo. It evaluated the growth hormone and IGF-1 axis. A seven-day hormone-response study does not establish a long-term increase in height velocity or final adult height. The former claim that it demonstrated a pediatric height increase has been removed.
What about sermorelin, ipamorelin, and related secretagogues?
Evidence that a compound changes growth hormone secretion does not establish that it increases height. The sources cited on this page do not establish a current, broadly applicable pediatric height indication or reliable centimeter outcomes for sermorelin, CJC-1295, ipamorelin, GHRP-2, or GHRP-6. The prior recommendation of sermorelin as a general option and ranking of experimental secretagogues have been removed.
Why growth-plate status and study outcomes matter
Height change depends on longitudinal bone growth at open growth plates. Studies must report an actual growth outcome in the relevant population to support a height claim. A change in GH or IGF-1, a predicted adult-height calculation, and measured adult height are different outcomes. The previous centimeter ranges, dosing arithmetic, storage timelines, and preparation directions were not supported by the cited height studies and have been removed.
Evidence summary
| Option | Human evidence measured | It does not establish |
|---|---|---|
| Mecasermin | Growth velocity in pediatric patients with severe primary IGF-1 deficiency | A general height treatment for children without the labeled diagnoses |
| GnRH agonists | Management of selected central precocious puberty cases | A general treatment for short stature |
| CJC-1295 | Short-term GH and IGF-1 response in healthy adults | Height velocity or adult height in children |
| MK-677 | Short-term GH and IGF-1 response in 18 children with growth hormone deficiency | Long-term growth velocity or final adult height |
| Other secretagogues | No height outcome established by sources cited here | Reliable centimeter gains or a validated height protocol |
Sources
- DailyMed: U.S. INCRELEX (mecasermin) prescribing information, indications and clinical studies.
- Teichman SL, et al. CJC-1295 pharmacokinetic and pharmacodynamic trials in healthy adults. PMID 16352683.
- Hawkes CP, et al. Ibutamoren study of the GH-IGF-1 axis in children with growth hormone deficiency. PMID 11452249.
- Endocrine Society. Central precocious puberty guideline, 2026.
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →